| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
beta-Amyrin acetate targets HMG-CoA reductase as an inhibitor. By inhibiting HMG-CoA reductase, it reduces cholesterol synthesis, contributing to its anti-hyperlipidemic activity. The compound also exhibits anti-inflammatory, antifungal, and anti-diabetic activities. Its antioxidant activity (IC₅₀ = 158.2 μg/mL) is mediated through free radical scavenging. beta-Amyrin acetate's multi-targeted mechanism makes it a valuable compound for studying triterpenoid pharmacology.
|
|---|---|
| ln Vitro |
β-Amyrinacetate (50 μg/mL) prevents human red blood cell hemolysis brought on by heat and hypotonic stress [1]. HMG-CoA reductase is present in β-aromatic resin acetate (5–100 μM), and it inhibits the active HMG CoA reductase [2]. All Candida fungus studied were suppressed by β-Aramacetate (7.8-1000 μg/mL, 48 hours), with MIC values ranging from 30 to 250 μg/mL [4].
In vitro, beta-amyrin acetate has a high antioxidant potential with an IC₅₀ value of 158.2 μg/mL. It inhibits HMG-CoA reductase. The compound exhibits cytotoxicity and could be a viable source of antioxidant and cytotoxic agents in cancer chemotherapy. It has potent anti-inflammatory, antifungal, anti-diabetic, and anti-hyperlipidemic activities. In cell-based assays, beta-amyrin acetate treatment results in reduced inflammation, inhibition of fungal growth, and reduced cholesterol synthesis. |
| ln Vivo |
Mice's xylene-induced ear edema was considerably reduced by β-Amylin acetate (100 μg/ear, single dosage) applied to the front surface of the right ear [1]. In adult albino rats, β-Aramid acetate (4 mg/100 g, intraperitoneal injection, daily for 6 days) shown considerable anti-inflammatory action (43.6%) [3]. In liver homogenates of both normal and arthritic rats, subcutaneous injection of beta-amyrin acetate (4 mg/100 g, once day for 10 days) boosts the activity of ATP-phosphohydrolase [3].
In vivo, beta-amyrin acetate has been studied for its anti-inflammatory, antifungal, anti-diabetic, and anti-hyperlipidemic activities. As a triterpenoid, it has potential therapeutic applications in the treatment of inflammatory diseases, diabetes, and hyperlipidemia. However, detailed in vivo efficacy data are limited. The compound is primarily used as a research tool and analytical standard. Comprehensive in vivo studies are needed. |
| Enzyme Assay |
In vitro enzyme assays for beta-amyrin acetate involve measuring its inhibition of HMG-CoA reductase activity. The enzyme is incubated with varying concentrations of beta-amyrin acetate in the presence of its substrate, and the enzymatic activity is measured spectrophotometrically. The compound's antioxidant activity is assessed using DPPH or ABTS assays. Its anti-inflammatory activity is assessed by measuring the inhibition of COX or LOX enzymes. These assays confirm the compound's multi-targeted mechanism.
|
| Cell Assay |
In vitro cell-based assays for beta-amyrin acetate evaluate its anti-inflammatory, antifungal, and anti-diabetic activities. Cells such as macrophages are cultured and treated with beta-amyrin acetate, and the production of inflammatory mediators is measured by ELISA. Antifungal activity is assessed by measuring the inhibition of fungal growth. Anti-diabetic activity is assessed by measuring glucose uptake or insulin secretion. These assays confirm the compound's functional activity.
|
| Animal Protocol |
Animal/Disease Models: xylene-induced local edema model of mouse ear [1]
Doses: 50 and 100 μg/ear (5 μL) Route of Administration: applied to the front surface of the right ear Experimental Results: Inhibition of xylene-induced mouse ear edema Edema Animal/Disease Models: adult albino rat [3] Doses: 4 mg/100g, daily, for 6 days Route of Administration: intraperitoneal (ip) injection Experimental Results: demonstrated significant anti-inflammatory activity, the average weight of granulation tissue after 6 days was 9.2 mg. In vivo animal experiments for beta-amyrin acetate have been conducted in models of inflammation, diabetes, and hyperlipidemia. Animals are treated with beta-amyrin acetate, and inflammatory markers, blood glucose levels, and lipid profiles are assessed. The compound's effects on disease progression are evaluated. Pharmacokinetic studies are conducted to determine the compound's absorption, distribution, metabolism, and excretion. Comprehensive in vivo studies are ongoing. |
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) data for beta-amyrin acetate are limited. The compound has a molecular weight of 468.8 g/mol and a molecular formula of C₃₂H₅₂O₂. It is a triterpenoid with low water solubility. The compound's metabolic stability, half-life, and bioavailability have not been fully characterized. Comprehensive ADME studies are needed.
|
| Toxicity/Toxicokinetics |
The toxicity profile of beta-amyrin acetate has not been extensively characterized. As a triterpenoid, it is generally considered to have low toxicity. However, the compound should be handled with appropriate safety precautions in the laboratory. For research use only, not for human therapeutic use without proper authorization. Comprehensive toxicological studies are needed.
|
| References |
|
| Additional Infomation |
β-Amyrin acetate is a triterpenoid compound. It has been reported to exist in Scutellaria barbata, Euphorbia multiflora, and other organisms with relevant data.
beta-Amyrin acetate is a triterpenoid with potent anti-inflammatory, antifungal, anti-diabetic, and anti-hyperlipidemic activities. It has a high antioxidant potential with an IC₅₀ of 158.2 μg/mL. beta-Amyrin acetate inhibits HMG-CoA reductase. It exhibits cytotoxicity and could be a source of antioxidant and cytotoxic agents in cancer chemotherapy. beta-Amyrin acetate is a research tool and analytical standard. |
| Molecular Formula |
C32H52O2
|
|---|---|
| Molecular Weight |
468.75408
|
| Exact Mass |
468.396
|
| CAS # |
1616-93-9
|
| PubChem CID |
92156
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
505.1±49.0 °C at 760 mmHg
|
| Flash Point |
256.2±17.4 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.529
|
| LogP |
11.95
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
34
|
| Complexity |
897
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
CC(=O)O[C@H]1CC[C@]2([C@H](C1(C)C)CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C)C)C)C
|
| InChi Key |
UMRPOGLIBDXFNK-ZYGITSNFSA-N
|
| InChi Code |
InChI=1S/C32H52O2/c1-21(33)34-26-13-14-30(7)24(28(26,4)5)12-15-32(9)25(30)11-10-22-23-20-27(2,3)16-17-29(23,6)18-19-31(22,32)8/h10,23-26H,11-20H2,1-9H3/t23-,24-,25+,26-,29+,30-,31+,32+/m0/s1
|
| Chemical Name |
[(3S,4aR,6aR,6bS,8aR,12aR,14aR,14bR)-4,4,6a,6b,8a,11,11,14b-octamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1333 mL | 10.6667 mL | 21.3333 mL | |
| 5 mM | 0.4267 mL | 2.1333 mL | 4.2667 mL | |
| 10 mM | 0.2133 mL | 1.0667 mL | 2.1333 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
